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Background: Health outcomes for Indigenous Australians with diabetes in remote areas remain poor, including
high rates of avoidable complications which could be reduced with better primary level care. We aimed to evaluate
the effectiveness of a community-based health-worker led case management approach to the care of Indigenous
adults with poorly controlled type 2 diabetes in primary care services in remote northern Australia.
Methods: Two hundred and thirteen adults with poorly controlled diabetes (HbA1c > 8.5%) and significant
comorbidities in 12 remote communities were randomly assigned by service cluster to receive chronic care
co-ordination from a community-based health worker supported by a clinical outreach team, or to a waitlist control
group which received usual care.
Results: At baseline, mean age of participants was 47.9 years, 62.4% were female, half were Aboriginal and half
identified as Torres Strait Islander, 67% had less than 12 years of education, 39% were smokers, median income was
$18,200 and 47% were unemployed. Mean HbA1c was 10.7% (93 mmol/mol) and BMI 32.5. At follow-up after
18 months, HbA1c reduction was significantly greater in the intervention group (−1.0% vs −0.2%, SE (diff) = 0.2,
p = 0.02). There were no significant differences between the groups for blood pressure, lipid profile, BMI or renal
function. Intervention group participants were more likely to receive nutrition and dental services according to
scheduled care plans. Smoking rates were unchanged.
Conclusions: A culturally safe, community level health-worker led model of diabetes care for high risk patients can
be effective in improving diabetes control in remote Indigenous Australian communities where there is poor access
to mainstream services. This approach can be effective in other remote settings, but requires longer term evaluation
to capture accrued benefits.
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Keywords: Type 2 diabetes, Australian aboriginal adults, Primary health care, Indigenous health workers* Correspondence: robyn.mcdermott@jcu.edu.au
1University of South Australia, 101 Currie St, Adelaide, SA 5001, Australia
2James Cook University, 1 James Cook Drive, Townsville City, QLD 4811,
Australia
© 2015 McDermott et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
McDermott et al. BMC Health Services Research  (2015) 15:68 Page 2 of 8Background
Indigenous Australians have the highest prevalence and
incidence of diabetes in Australia [1] and also suffer high
rates of preventable complications [2]. Many of these
complications can be prevented with better primary care
level management however access to culturally appropri-
ate high quality diabetes care is not always evident, espe-
cially in remote settings where there is high turnover of
health staff. Australian Indigenous adults with type 2
diabetes are on average 10 years younger, have poor gly-
cemic control and lower levels of preventive service up-
take compared to non-Indigenous adults with diabetes
in a national sample [3]. As a consequence there are
high rates of diabetes-related avoidable hospitalisations
for people in remote settings [4]. Previous reports sug-
gest that community health workers can contribute to
improved diabetes care and outcomes in high risk and
under-served patients in Australia [5,6] and elsewhere
through more effective communication and culturally
appropriate self-management support, although until
recently, few studies use robust randomized controlled
designs. Interventions with the strongest outcomes in-
cluded “cultural tailoring of the intervention, community
educators or lay people leading the intervention, one-
on-one interventions with individualized assessment and
reassessment, incorporating treatment algorithms, focu-
sing on behavior-related tasks, providing feedback, and
high-intensity interventions (>10 contact times) deli-
vered over a long duration (≥6 months)” [7].
We report the results of a cluster randomised con-
trolled trial, “Getting better at chronic care” which
aimed to evaluate the impact of a case management ap-
proach by local community-based health workers sup-
ported by an Indigenous clinical outreach team in 12
primary care services in remote far north Queensland




The study setting was 12 small remote communities
(Indigenous population range 260–3,000) in far north
Queensland where the majority of the population was
Aboriginal or Torres Strait Islander, served by a single
provider and where the health service had agreed to par-
ticipate in the trial. Primary health care is provided by
either a community-controlled service (n = 4) or the
Queensland Government (n = 8). The distance to the
nearest tertiary hospital is between one and 12 hours by
road or air.
The unit of randomisation was the community health
service which was allocated to either the health-worker
led case management intervention or to a waitlist con-
trol group (where the intervention was provided after18 months). Following patient recruitment and baseline
data collection, the 12 services were randomly allocated
(names out of a hat) to either the intervention (n = 6) or
waitlist group (n = 6). The study was not blinded as the
allocation arm was known following recruitment and
baseline data collection and the study was designed as a
pragmatic trial reflecting effectiveness in real world prac-
tice [8]. The data reported here were collected at two
timepoints. Baseline data at the time of recruitment
(2011) and follow-up data in 2013.
The study was approved by the Cairns and Hinterland
Institutional Ethics Committee with support from the
peak Aboriginal and Torres Strait Islander Health Coun-
cils. The trial is registered as a clinical trial, ANZCTR
number 12610000812099.
Study sample
Patient eligibility criteria included having type 2 diabetes
and at least one major comorbidity, age 18 or more, poor
glycemic control (HbA1c > =8.5% or 69 mmol/mol), men-
tally competent and able to provide informed consent,
and obtaining regular care from the identified health ser-
vice. Exclusion criteria were major mental ill health (major
psychosis or depression requiring inpatient treatment) or
substance misuse, renal dialysis or end-stage renal disease,
a cancer diagnosis or current pregnancy. Eligible patients
were identified from their records by the health service
staff, who then approached them to be in the trial. Enrol-
ment occurred between December 2011 and July 2012.
Baseline (2011) and follow-up (2013) interviews were con-
ducted by Indigenous researchers in either plain English
or Creole, depending on the preference of the patients.
The trial was powered to demonstrate a reduction in
median HbA1c by 1.0% over 18 months compared to
baseline, as the primary outcome measure. This estimate
was based on a mean drop of 1.3% HbA1c over one year
(from 9.9% to 8.6%, following initiation of intensive drug
treatment in T2DM) reported by a large US Health
Maintenance Organization [9]. A sample size of 49 in
each group would have 90% power to detect a difference
in mean HbA1c between the intervention and control
group after 18 months of 1.0%, assuming that the
common standard deviation was 1.5% using a two group
t-test with a 0.05 two-sided significance level. With 12
communities (6 intervention, 6 control), this would re-
quire 9 subjects per community. With adjustment for
clustering, assuming a design effect of 1.2 derived from a
similar study [10], the required number of subjects per
community is 11 for the primary outcome, or 132 in
total [11]. However, due to potential difficulty of main-
taining subjects in these communities in the trial, high
rates of mobility, and the potential for a more modest ef-
fect size in this group, we aimed to recruit 300 subjects.
In the event, 327 patients were assessed by the health
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providing written informed consent. Over the study
period, 22 patients (10%) were lost to follow-up: 6 died,
15 moved away from the community permanently and
one withdrew. More patients in the intervention group
than the waitlist group were lost to follow up (Figure 1).
Intervention
Each site allocated to the intervention arm recruited an
Indigenous health worker resident in the community
(selected by the health service) to work as part of the
primary care team, and allocated a caseload of between
9 and 26 clients. The health workers with low caseloads
worked part-time. All health workers at the commence-
ment of the study received an intensive 3-week training
in clinical aspects of diabetes and other chronic con-
dition care, including how to support patients in self-Figure 1 CONSORT flow diagram: getting better at chronic care clustemanagement skills, advice on medications, routine foot
care, nutrition, smoking cessation, follow up referrals to
other providers, and scheduled tests. The roles of the
health workers included helping patients make and keep
appointments, understand their medications and nutri-
tion and the effects of smoking and where appropriate,
work with the family to help support the patient in self-
management. Home visits and out-of-clinic care were
features of the trial, however visits were conducted ac-
cording to the patients’ preferences.
The curriculum included specific training and prac-
tice in:
 Rationale for the chronic care model and
evidence-based management and treatment
goals in diabetes, hypertension, COPD, renal
disease and CHD.r RCT.
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visits, including basic diabetes care (scheduled
clinical checks and blood tests, counselling and
referral as per the clinical guidelines supported by
the clinical team).
 Working in a primary care team, with clear roles
and responsibilities of team members.
 Engaging with families and using local resources to
support effective client self-management.
During the 18 month intervention period, the health
workers attended two workshops where they underwent
refresher training, including in Good Clinical Practice
and reflective practice. During these sessions, they re-
ported on their patients’ progress and shared approaches
to problem solving with the clinical support team and
peers.
Measures
The primary outcome measure for this trial, glycemic
control (HbA1c) was measured by Queensland Medical
Laboratories using standard high-pressure liquid chro-
matography methods. Blood pressure, height, weight,
serum fasting lipids (Cholesterol fractions and trigly-
cerides) were abstracted from clinic files and electronic
records. Taking insulin was defined as having any of
long-acting, medium- or short-acting insulin. Albumi-
nuria was defined as urinary ACR > =3.4 mg/mmol.
Estimated glomerular filtration rate (eGFR) was calcu-
lated from serum creatinine using the CKD-EPI formula,
where GFR = 141 ×min (Scr/κ,1) α ×max (Scr/κ,1)-1.209 ×
0.993Age × 1.018 [if female] × 1.159 [if black], where Scr is
serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for
males, α is −0.329 for females and −0.411 for males, min
indicates the minimum of Scr/κ or 1, and max indicates
the maximum of Scr/κ or 1 [12].
Test of Functional Health Literacy for Adults
(TOFHLA) [11] was administered at study enrolment to
all participants to gauge the patients’ general under-
standing of health messages and procedures. In general,
TOFHLA was scored highly in both groups, and it was
concluded that they would not have major difficulty
working with the diabetes care team.
Quality of Life was estimated using the Assessment of
Quality of Life (AQoL) instrument, a multi-attribute
utility instrument developed using Australian impor-
tance weights [13]. Socio-demographic data was by self-
report, including years of formal education, household
income, employment, food insecurity (“Do you fre-
quently not have enough money to buy food?”), current
smoking and medication adherence.
Guideline recommended clinical checks, including
General Practitioner Management Plans (GPMP) and
specialist referrals [14], were abstracted from primarycare records for the 18 months prior to the baseline and
follow-up assessments. For patients with clinical indica-
tions, appropriate medication use (as indicated in the
clinical guidelines) was recorded, including insulin, sta-
tins, ACEi or ARB drugs, vaccination.
Implementation Fidelity and “dose” was estimated
through diaries kept by the IHWs which recorded time
spent on specific intervention-related tasks versus other
clinical work, as we anticipated that due to the small size
of the communities and the limited number of health
staff, that the trial workers would be called upon to per-
form regular acute clinical care to the general patient
population.
Statistical analysis
Baseline demographic and clinical data were analysed
for differences between intervention and waitlist patients
using t-tests, Wilcoxon rank sum tests and chi-square
tests as appropriate. At follow-up all analyses were on
an intention to treat basis. The 22 people who had either
died or were lost to follow up were included in the data-
set; however, their 18 month follow-up results were left
blank. Analysis was by Generalized Estimating Equations
(GEE), using a Gaussian family and identity link func-
tion. The GEE regression models used Group, Time, and
a Group × Time interaction term as predictor variables.
The formal test of an intervention effect was whether or
not the coefficient for the interaction term was statisti-
cally significant at the 5% level. An initial analysis using
a mixed effects model showed that adjustment for clus-
tering by community made little difference, based on a
likelihood ratio test. That being the case, further models
were not adjusted for clustering. There were a few cases
where data was available for only one time point. Where
there was missing data, a second analysis was performed
used multiple imputation with 20 copies of the dataset
and using a regression approach for imputation. Non-
parametric tests (ranksum test) were used to examine
HbA1c change by GPMP exposure between groups. A
further analysis was done looking at the impact of the ser-
vice model (Community controlled versus Government
provided) on the likelihood of clinical change, indepen-
dently of group allocation.
All analyses were done using Stata version 13.
Results
At baseline, there were no significant differences bet-
ween allocation groups in age (mean age 47.9 years), sex
ratio (62% women), employment status, years of school-
ing, median household income, self-reported food inse-
curity, household size, median AQoL score on the
mental health scale, smoking prevalence, HbA1c (10.7%)
and mean BMI (32.5). The intervention group scored
lower on the health literacy test (Table 1).
Table 1 Baseline socio-demographic characteristics of study participants (SD or %)
Control (95% CI) Intervention (95% CI) All (95%CI) p-value
Number of participants 113 100 213
Mean age (years) 47.8 (46.2-49.5) 47.9 (45.8-50.0) 47.9 (46.6-49.2) 0.948
Number (%) women 66.4 (57.6-75.2) 58.0 (48.2-67.8) 62.4 (55.9-69.0) 0.208
Unemployed (%) 52.2 (42.9-61.5) 40.0 (30.3-49.7) 46.5 (39.7-53.2) 0.204
Did not complete 12 years education (%) 61.9 (52.9-71.0) 73.0 (64.2-81.8) 67.1 (60.8-73.5) 0.344
Median annual (IQR) household income ($) 17420 (12480–33800) 20215 (13585–31200) 18200 (13000–32500) 0.598
“Not enough money for food” (%) 40.7 (31.6-49.9) 37.0 (27.4-46.6) 39.0 (32.4-45.6) 0.580
Median score (IQR) TOFLA 90.0 (81.1-94.1) 80.6 (64.9-89.0) 86.1 (71.5-92.1) <0.001
No of people per household median (IQR) 5 (3–7) 4 (3–7) 4 (3–7) 0.608
Median AQoL mental health score (IQR) max = 1 0.93 (0.89-0.98) 0.93 (0.91-0.94) 0.93 (0.89-0.95) 0.688
Current smoker (%) 37.6 (28.4-46.8) 40.2 (30.3-50.1) 38.8 (32.1-45.5) 0.231
Mean BMI (kg/m2)* 33.0 (31.2-34.9) 31.9 (29.9-33.9) 32.5 (31.1-33.8) 0.434
*Missing data: BMI n =113.
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in the intervention group had a current GP Management
Plan (GPMP) for diabetes compared to 35.5% (26.3-44.7)
in the waitlist group (OR 1.23, 95% CI, 0.72-2.22). There
was no association between having a GPMP at follow-up
and HbA1c change from baseline. This may be due to
the fact that many GPMPs were done within 6 months
of the follow-up data collection point, so the chance for
the GPMP to have an immediate impact would be small.
Further follow up may show a stronger relationship bet-
ween having a GPMP and improved clinical indicators.Table 2 Clinical care process at baseline and follow up (%)
Baseline
Control n = 113 Inter
No % (95% CI) No
GPMP for diabetes % 19 22.2 (13.5-30.9) 28
Foot check% 50 44.2 (35.0-53.5) 31
Seen by DM educator % 46 40.7 (31.6-49.9) 52
Seen by dietician % 22 19.5 (12.1-26.8) 30
Dentist check % 20 17.7 (10.6-24.8) 13
ECG check% 37 32.7 (24.0-41.5) 42
Eye check % 54 47.8 (38.5-57.1) 42
Smoker % 38 34.5 (25.6-43.5) 34
Blood glucose self-monitor % 45 40.9 (31.6-50.2) 46
Taking insulin% 55 48.7 (39.4-58.0) 40
Dislipidemia % 83 73.5 (65.2-81.7) 84
Taking lipid lowering medicines% 91 81.3 (73.9-88.6) 77
Albuminuria and taking ACEi or ARB drugs 46 88.5 (79.6-97.3) 47
Adherent to all medicines 53 46.9 (37.6-56.2) 55
Had Fluvax 50 44.2 (35.0-53.5) 66
The proportion calculated on available records. Taking insulin including having eith
ACR > =3.4 mg/mmol; taking lipid lowering medicines including statin, fibrate, andOther clinical care processes, including routine checks
and specialist referrals, medications and self-reported
smoking and medication adherence at baseline and
follow-up, are summarised in Table 2. Intervention
group patients were significantly more likely to have
seen a dietician and dentist and slightly more likely to
have seen a diabetes educator, be taking insulin and
having influenza vaccination. Waitlist group patients
showed greater self-reported adherence to prescribed
medicines and were slightly more likely to have had an
eye examination and be self-monitoring for glucose.Endpoint (excluding 22 loss of follow up)
vention n = 100 Control n = 107 Intervention n = 84
% (95% CI) No % (95% CI) No % (95% CI)
40.3 (29.2-51.4) 24 29.6 (19.5-39.7) 27 40.3 (28.4-52.2)
31.0 (21.8-40.2) 38 35.5 (26.3-44.7) 26 31.0 (20.9-41.0)
52.0 (42.1-61.9) 41 38.3 (29.0-47.6) 44 52.4 (41.6-63.2)
30.0 (20.9-39.1) 21 19.6 (12.0-27.2) 37 44.0 (33.3-54.8)
13.0 (6.3-19.7) 9 8.4 (3.1-13.7) 15 17.9 (9.6-26.5)
42.0 (32.2-51.8) 34 43.9 (34.4-53.4) 35 40.5 (29.8-51.1)
42.0 (32.2-51.8) 56 52.3 (42.8-61.9) 37 44.0 (33.3-54.8)
35.1 (25.5-44.7) 33 31.2 (22.4-40.4) 34 41.5 (30.7-52.2)
46.0 (36.1-55.9) 63 59.4 (50.0-68.9) 44 52.4 (41.6-63.2)
40.0 (30.3-49.7) 47 43.9 (34.4-53.4) 40 47.6 (36.8-58.4)
84.0 (76.7-91.3) 91 85.0 (78.2-91.9) 76 90.5 (84.1-96.8)
77.0 (68.7-85.3) 87 82.1 (74.7-89.5) 62 73.8 (64.3-83.3)
88.7 (80.0-97.4) 58 82.9 (73.9-91.8) 51 89.5 (81.4-97.6)
55.0 (45.1-64.9) 57 53.3 (43.7-62.8) 41 48.8 (38.0-59.6)
66.0 (56.6-75.4) 51 47.7 (38.1-57.2) 50 59.5 (48.9-70.2)
er long-term, medium-term or short-term insulin. Albuminuria defined as
lipase inhibitors.
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ally very low uptake of lipid lowering treatment in both
groups, and the high smoking rates were unchanged.
Appropriate management of albuminuria was high in
both groups.
There was a significant decrease in HbA1c of 1%
from baseline in the intervention group, from 10.8%
(95 mmol/mol) to 9.8% (84 mmol/mol) compared to the
waitlist group, which showed a less marked decrease of
0.2% from 10.6% (92 mmol/mol) to 10.3% (89 mmol/mol),
(p = 0.018). More in the intervention group achieved
at least a 0.5% interval reduction in HbA1c (67.5%,
57.3-77.7), than in the waitlist group (48.6%, 38.9-58.2).
There were small improvements in both groups for total
cholesterol, LDL cholesterol, cholesterol: HDL ratio, with
slightly better results in the intervention group. Blood
pressure and weight decreased in the waitlist group and
increased slightly in the intervention group. None of these
effects were statistically significant at the 5% level (Tables 3
and 4).
Implementation “dose” (time reported by the Health
Workers spent on project-specific tasks) ranged from
43% to 78% over the intervention period. Thus we ex-
pected some diminution of effect in intervention sites.
The impact of Health Service Model (community
controlled (CC) versus not CC) on the likelihood of a
participant having a GPMP was explored independently
of whether the trial site was in the intervention or the
control group allocation. The percentage of GPMPs
completed in sites with a community-controlled service
was 71.0% compared to 23.5% among the non-CC sites
(OR = 3.0, 95% confidence interval, 1.2-7.5 after adjust-
ment for clustering) (Table 5). However there were noTable 3 Clinical measures at baseline and follow-up by group
Pathology tests Baseline
Control n = 113 Intervention n = 100
No. Mean SD No. Mean S
HbA1c 113 10.6 1.87 99 10.8 2
s.creatinine 97 77.5 43.8 88 77.7 3
eGFR* 97 109.8 26.7 88 114.1 3
UACR 78 63.9 138.9 73 71.3 1
Cholesterol 87 4.6 1.3 81 4.5 1
Trig 86 2.5 1.9 81 2.1 1
HDL 72 1.1 0.6 79 0.9 0
LDL 65 2.6 1.0 76 2.7 1
Chol-HDL ratio 72 5.2 1.6 77 5.4 1
Weight 89 91.4 19.3 87 89.7 2
BP systolic 109 134.0 20.9 95 127.9 1
BP diastolic 104 81.0 11.1 92 77.7 1
*Calculated from serum creatinine using CKD-EPI formula.differences in clinical measures between CC and non-
CC sites at follow-up.
Discussion
Type 2 diabetes and associated cardiovascular and renal
disease contribute more than 60% to the 11–13 year life
expectancy gap experienced by Indigenous Australians
[15]. We found that a health-worker led case management
approach to care of high risk adults with type 2 diabetes
in remote communities in Australia was effective in im-
proving some diabetes care processes and glycemia over
18 months. This model has been demonstrated recently in
other countries and similarly disadvantaged and high risk
populations [16-19] using robust evaluations, and suggest
our results are generalizable to other similar rural or re-
mote settings. However the relatively short-term (<2 years)
follow-up in these studies does not allow capture of the
longer term benefits. Economic evaluation therefore relies
on modelling rather than empirical estimates of costs and
benefits, although most reports favour low-cost primary
care level interventions [20].
Limitations to our study include lower than expected
patient recruitment, small numbers in two of the inter-
vention sites, a relatively high loss to follow up (10%)
which was higher in the intervention group and missing
data for some of the secondary clinical endpoints. The
latter was due to the pragmatic nature of the trial where
clinical data was extracted from patient records. Loss to
follow-up in the intervention group did not appear to be
related to the trial itself, but to family circumstances,
where a greater proportion moved out of the commu-
nity. Other factors which potentially limited the imple-
mentation effectiveness of the study were major health, absolute values
Endpoint (excluding 22 lost to follow up)
Control n = 107 Intervention n = 84
D No. Mean SD No. Mean SD
.0 105 10.3 2.2 84 9.8 2.3
9.7 102 92.0 85.0 83 107.4 138.6
1.0 102 104.5 30.8 83 103.3 33.4
69.4 96 102.8 233.9 79 92.1 167.9
.3 100 4.7 1.3 79 4.4 1.4
.4 100 2.7 1.8 79 2.5 1.8
.2 99 0.9 0.2 78 0.9 0.2
.1 95 2.6 1.1 71 2.4 0.9
.6 99 5.0 1.4 77 5.0 1.7
2.6 92 87.4 18.6 81 91.0 23.1
6.7 100 133.6 19.4 84 132.5 17.7
0.4 103 81.3 11.4 84 77.8 9.9
Table 4 Differences between baseline and follow-up by group
Measure Group No. Mean difference Std. error of the difference 95% CI mean lower 95% CI mean upper
HbA1c Control 105 −0.2 0.2 −0.7 0.2
Intervention 83 −1.0 0.2 −1.4 −0.5
S Creatinine Control 89 18.9 6.9 5.2 32.6
Intervention 74 32.7 13.4 6.0 59.5
eGFR* Control 89 −7.2 1.8 −10.7 −3.7
Intervention 74 −10.3 3.1 −16.5 −4.1
UACR Control 71 41.2 25.3 −9.3 91.8
Intervention 58 17.6 20.1 −22.7 57.9
Cholesterol Control 64 −0.3 0.2 −0.6 −0.02
Intervention 60 −0.6 0.2 −0.9 −0.3
Triglycerides Control 79 0.1 0.2 −0.4 0.5
Intervention 64 0.2 0.2 −0.1 0.5
HDL Control 64 0.06 0.02 0.02 0.09
Intervention 62 0.06 0.02 0.02 0.1
LDL Control 56 −0.1 0.1 −0.3 0.2
Intervention 57 −0.3 0.1 −0.6 −0.1
Cholesterol-HDL ratio Control 64 −0.3 0.2 −0.6 −0.02
Intervention 60 −0.6 0.2 −0.9 −0.3
Weight Control 72 −1.5 0.6 −2.7 −0.3
Intervention 71 −0.6 0.7 −2.0 0.8
*Calculated using CKD-EPI formula.
Values in this table calculated as Endpoint- Baseline.
Please note, this calculation is based on only those patients for whom data was collected at both time points excluding 22 loss of follow up. There are a few cases
where data was available for only one time point.
McDermott et al. BMC Health Services Research  (2015) 15:68 Page 7 of 8system reform occurring in the Queensland government
health services generally during the life of the trial,
which limited the ability of the service to recruit and
retain essential staff. These changes disproportionately
affected 3 of the intervention sites. Process evaluation
found that all six health workers experienced higher
workloads as the services pressured them to undertake
clinical work in addition to their study caseload. This
tended to dilute the potential impact of their work on
the care of study patients.Conclusions
In summary, we have demonstrated a significant and
favourable impact on some diabetes care processes and
glycemic control of a community health worker-led modelTable 5 Presence of a GPMP at T3 by health service
model, independent of trial group allocation
GPMP CC n = 62 Not-CC n = 151
No. % (95% CI) No. % (95% CI)
No 18 29.0 (17.6-40.5) 114 76.5 (69.6-83.4)
Yes 44 71.0 (59.5-82.4) 35 23.5 (16.6-30.4)of diabetes care in high risk disadvantaged populations in
remote Australia. A longer term evaluation may enable
more complete capture of further benefits, including eco-
nomic impact on the health service and patient-important
outcomes. As the rising incidence of obesity, diabetes and
associated complications rises globally, it is clear that the
current health care workforce, especially in low- and
middle-income countries will not be able to adequately
manage new and established cases using current work-
force models [21]. Community Health Workers in high in-
come countries have been shown to contribute
significantly to chronic disease management especially in
hard-to-reach populations [22], although urban settings
might offer different challenges [23] and may play a more
important role in the primary care team as the diabetes
epidemic increases in these groups.
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